Work

A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53-wild type and MDM2-amplified advanced or metastatic solid tumors (MANTRA-2).

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.tps3165

Authors: Ecaterina Elena Dumbrava, Glenn J. Hanna, Gregory Michael Cote, Tom Stinchcombe, Melissa Lynne Johnson, Christopher Chen, Siddhartha Devarakonda, Naisargee Shah, Feng Xu, Robert Charles Doebele, Mrinal M. Gounder

Institutions: The University of Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute, Massachusetts General Hospital, Duke University, Duke Medical Center, Duke Cancer Institute, Tennessee Oncology, Stanford Medicine, Stanford University, Washington University in St. Louis, Memorial Sloan Kettering Cancer Center

Language: English

Topic: Cancer-related Molecular Pathways

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4286295703

Cites:

Cited by: 7

Related to: 10